We are pleased to announce a key update to ImpriMed’s Personalized Prediction Profile (PPP) and Drug Response Predictions (DRP) – specifically for Single Drug Response Prediction (SDRP) models. Our R&D team has enhanced the predictive performance of our live cell and AI-driven platform, enabling us to deliver even more reliable and clinically meaningful drug response predictions.
Internal validation studies have shown that the updated SDRP models now deliver:
- 16% average improvement in predictive accuracy
- 25% average improvement in specificity
- 22% average improvement in positive predictive value (PPV)
In rare cases, some Personalized Prediction Profile or Drug Response Predictions reports may include predictions for less than 13 drugs. When this occurs, we will focus on providing predictions for the preferred drugs you selected.
We are grateful to the oncology teams who continue to share patient outcomes with us. Your contributions are vital to advancing precision oncology and improving care for future patients. We look forward to continuing to grow and innovate together.
Best regards,
Team ImpriMed